Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 13/20 | 0.45 |
| ▸ | CPB1 | P15086 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14523660 | 1.00 | CPB2 (0.45) | CPB2CPB1CYP1A2SLC1A3ALPI | |
| SCHEMBL2489370 | 0.84 | CPB2 (0.46) | CPB2CPB1CYP1A2ALPIPKM | |
| SCHEMBL8760849 | 0.84 | CPB2 (0.61) | CPB2CPB1CYP1A2 | |
| SCHEMBL7741446 | 0.84 | CPB2 (0.61) | CPB2CPB1CYP1A2 | |
| SCHEMBL14523640 | 0.84 | CPB2 (0.41) | CPB2CPB1CYP1A2SLC1A3 | |
| SCHEMBL7741830 | 0.82 | CPB2 (0.50) | CPB2CPB1CYP1A2 | |
| SCHEMBL13634030 | 0.82 | CPB2 (0.42) | CPB2CPB1CYP1A2SLC1A3 | |
| SCHEMBL22092361 | 0.82 | CPB2 (0.44) | CPB2CPB1CYP1A2ALPIPKM | |
| SCHEMBL14344753 | 0.82 | CPB2 (0.42) | CPB2CPB1CYP1A2ALPIPKM | |
| SCHEMBL10583023 | 0.82 | CPB2 (0.64) | CPB2CPB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3704 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141054-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FUSION PROTEIN AND USE THEREOF | 苏州康宁杰瑞生物科技有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024140903-A1 | COMPOSITION OF CD40-BINDING MOLECULE AND PHARMACEUTICAL USE THEREOF | 苏州盛迪亚生物医药有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024120518-A1 | IL-17A ANTIBODY FORMULATION AND USE THEREOF | 上海华奥泰生物药业股份有限公司 | 2024-06-13 | — | — | WO | claimed |
| WO-2024088293-A1 | COMPOSITION COMPRISING ANTI-MASP2 ANTIBODY, AND PHARMACEUTICAL USE | 江苏恒瑞医药股份有限公司 | 2024-05-02 | — | — | WO | claimed |
| CN-117942300-A | Liquid formulations comprising anti-IL-17 antibodies | 甘李药业股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-111375059-B | anti-GITR antibody pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-112543647-B | TIM3 antibody pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-113713094-B | anti-IL-6R antibody pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-20240024498-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | US | claimed |
| US-20240016931-A1 | ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | claimed |
| CN-102281901-A | Therapeutic protein formulations | — | 2011-12-14 | — | — | CN | claimed |
| EP-2371388-A2 | Antibody formulations | Genentech, Inc. (US) | 2011-10-05 | — | — | EP | claimed |
| EP-2358393-A1 | THERAPEUTIC PROTEIN FORMULATIONS | F.HOFFMANN-LA ROCHE AG (CH) | 2011-08-24 | — | — | EP | claimed |
| CN-101084015-B | Antibody formulations in histidine-acetate buffer | GENENTECH INC | 2011-08-10 | — | — | CN | claimed |
| WO-2010059787-A1 | THERAPEUTIC PROTEIN FORMULATIONS | GENENTECH, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20100015157-A1 | ANTIBODY FORMULATIONS | GENENTECH, INC. (US) | 2010-01-21 | — | — | US | claimed |
| CN-101084015-A | Antibody formulations in histidine-acetate buffer | GENENTECH INC (US) | 2007-12-05 | — | — | CN | claimed |
| EP-1802344-A2 | ANTIBODY FORMULATION IN HISTIDINE-ACETATE BUFFER | Genentech, Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044908-A2 | ANTIBODY FORMULATION IN HISTIDINE-ACETATE BUFFER | GENENTECH, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060088523-A1 | Antibody formulations | GENENTECH, INC. | 2006-04-27 | — | — | US | claimed |